New CAR-T therapy from Bristol, Bluebird effective but too costly, ICER finds

A new cell therapy for multiple myeloma likely provides "small to substantial" health benefits over commonly used drugs for patients sick with the blood cancer, but is priced too high to be cost-effective, according to the Institute for Clinical and Economic Review, an influential non-profit that reviews new drugs.